Latest Ratios: P/E Ratio -1.4x · EV/EBITDA N/A · ROE -181.6%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $215M | $161M | $183M | $668M | $761M | $1.7B | $1.2B | $1.1B | — | — | — |
| Enterprise Value | $186M | $131M | $192M | $633M | $650M | $1.4B | $1.2B | $1.0B | — | — | — |
| P/E Ratio → | -1.40 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 10.23 | 7.63 | 1.82 | 6.88 | 5.70 | 8.02 | 55.76 | 50.13 | — | — | — |
| P/B Ratio | 6.52 | 5.24 | 1.44 | 4.98 | 3.55 | 5.52 | 4.40 | 5.46 | — | — | — |
| P/FCF | — | — | — | — | — | 5.62 | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 5.56 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.23 | 1.91 | 6.52 | 4.87 | 6.66 | 55.82 | 48.17 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 4.67 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.1% | 54.1% | 100.0% | 90.9% | 100.0% | 8.5% | -643.5% | -373.8% | -163.9% | -700.8% | -3187.0% |
| Operating Margin | -692.8% | -692.8% | -144.2% | -156.3% | -103.2% | -18.0% | -925.1% | -539.2% | -207.0% | -874.9% | -3637.5% |
| Net Profit Margin | -679.2% | -679.2% | -118.4% | -134.3% | -99.8% | -17.5% | -901.6% | -496.7% | -188.8% | -869.6% | -3632.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -181.6% | -181.6% | -91.2% | -74.8% | -51.8% | -12.8% | -82.3% | -216.5% | — | — | — |
| ROA | -37.5% | -37.5% | -21.8% | -18.5% | -16.6% | -5.6% | -41.8% | -28.9% | -19.2% | -22.4% | -27.9% |
| ROIC | -159.2% | -159.2% | -92.6% | -112.7% | -168.6% | -19.5% | -69.4% | — | — | — | — |
| ROCE | -51.4% | -51.4% | -36.8% | -26.7% | -20.1% | -6.8% | -50.0% | -34.9% | -22.7% | -25.0% | -28.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.18 | 1.18 | 0.34 | 0.29 | 0.20 | 0.16 | 0.19 | 0.25 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.96 | 0.07 | -0.27 | -0.52 | -0.94 | 0.00 | -0.21 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -0.95 | — | — | -0.52 | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($66M) exceeds total debt ($36M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.83 | 3.83 | 3.40 | 3.18 | 7.74 | 5.37 | 6.19 | 5.77 | 22.48 | 8.50 | 33.90 |
| Quick Ratio | 3.83 | 3.83 | 3.40 | 3.18 | 7.74 | 5.37 | 6.19 | 5.77 | 22.48 | 8.50 | 33.90 |
| Cash Ratio | 3.68 | 3.68 | 3.31 | 3.08 | 7.60 | 5.27 | 6.07 | 5.70 | 22.27 | 1.18 | 33.67 |
| Asset Turnover | — | 0.07 | 0.21 | 0.16 | 0.17 | 0.25 | 0.04 | 0.05 | 0.09 | 0.02 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 7.07 | 13.03 | — | — | — | 19568.10 | 191.27 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 17.8% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $103M | $97M | $84M | $82M | $80M | $78M | $62M | $68M | $51M | $8M |
Imminent liquidity depletion risk
As reported in recent financial filings, Alector trades at a price-to-sales ratio of 9.81, a valuation that appears disconnected from fundamental performance and instead reflects speculative market pricing tied to the binary outcomes of the company's late-stage immuno-neurology clinical trials rather than any recurring earnings power.
The absence of a meaningful P/E or EV/EBITDA multiple underscores that investors are valuing the firm as a real option on its intellectual property rather than a going concern. This high P/S multiple warrants caution, as it suggests the market is pricing in a high probability of success for the INFRONT-3 study, leaving little margin for error should clinical data disappoint.
Based on the company's reported figures, the ROIC has consistently trended in negative territory, reaching -66.4% in 2025Q3, which indicates that the firm is currently destroying invested capital as it funds high-cost research initiatives without generating any offsetting returns from its clinical pipeline assets.
The persistent decay in ROIC reflects the structural challenge of funding long-duration biotech development in a high-cost environment. Investors should monitor whether the company can achieve a pivot toward positive returns, though current trends suggest that capital efficiency will remain strained until a commercial product is successfully brought to market.
According to recent quarterly balance sheet data, the current ratio has fluctuated significantly, settling at 5.25 in 2026Q1, yet this metric masks the underlying reality that cash reserves are rapidly depleting against the substantial ongoing operational expenses required to sustain the firm's late-stage clinical development programs.
While the current ratio appears superficially healthy, it is heavily influenced by the timing of collaboration-related receivables rather than liquid cash availability. The rapid erosion of the asset base suggests that the company's liquidity position is increasingly vulnerable, necessitating either a major milestone payment or dilutive financing in the near term.
As indicated by the company's financial statements, the price-to-sales ratio is frequently misapplied to Alector, as it obscures the fact that reported revenue is derived from lumpy, non-recurring collaboration milestones rather than sustainable product sales, rendering traditional valuation benchmarks largely irrelevant for assessing the firm's true economic value.
Analysts should instead focus on the cash-to-burn ratio or the enterprise value relative to the probability-adjusted net present value of the pipeline. Relying on P/S multiples in a pre-commercial biotech context risks misinterpreting accounting-driven revenue recognition as evidence of commercial traction, which may lead to an overestimation of the company's fundamental stability.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALEC stock.
Alector, Inc.'s current P/E ratio is -1.4x. This places it at the 50th percentile of its historical range.
Alector, Inc.'s return on equity (ROE) is -181.6%. The historical average is -101.6%.
Based on historical data, Alector, Inc. is trading at a P/E of -1.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Alector, Inc. has 54.1% gross margin and -692.8% operating margin.